FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Retatrutide vs Tirzepatide: Which Is Better, Dose for Dose?

Unlabeled research sample vials beside analytical equipment in a bright laboratory

Retatrutide usually comes up after someone has spent a few months on tirzepatide. Both are weekly Eli Lilly injections built on the same 39-amino-acid backbone, and retatrutide is the one that goes further: 28.3% average weight loss on its top dose in Phase 3, against 22.5% on tirzepatide’s.

The catch is that the two climb different ladders. Retatrutide tops out at 12mg and tirzepatide at 15mg, the milligrams don’t line up, and the first trial to put them in the same study hasn’t reported. A buyer moving between them has to match them by result instead, and on that measure retatrutide 4mg already lands close to tirzepatide 10mg.

Simms Research stocks both, Retatrutide (GLP-3) and Tirzepatide (GLP-2), in the same four vial sizes from 10mg to 60mg, with every batch tested by an independent lab for purity, identity and net content.

What is the difference between retatrutide and tirzepatide?

One receptor. Tirzepatide switches on two, GIP and GLP-1. Retatrutide switches on both of those plus the glucagon receptor, so where tirzepatide works mainly on how much is eaten, retatrutide adds a push on how much is burned. Side by side:

TirzepatideRetatrutide
ReceptorsGIP, GLP-1GIP, GLP-1, glucagon
Top trial dose15mg12mg
Weight loss, top dose22.5% at 72 weeks28.3% at 80 weeks
Starting dose2.5mg2mg
Half-lifeAbout 5 daysAbout 6 days
FDA statusApproved since 2022Filing planned early 2027
Research nameGLP-2GLP-3

How tirzepatide works

Tirzepatide is one peptide acting on two hormone receptors. GLP-1 is the appetite signal: it slows the stomach and turns hunger down in the brain. GIP adds insulin release and appears to soften some of the nausea GLP-1 brings. Tirzepatide matches the body’s own GIP and pulls at the GLP-1 receptor about a fifth as hard as natural GLP-1.

Its record is the longer of the two, from the SURMOUNT weight-loss trials and the SURPASS diabetes trials. In SURPASS-2 it beat semaglutide 1mg at every dose, lowering A1C by up to 2.30 points against 1.86 over 40 weeks (Frías, New England Journal of Medicine, 2021).

How retatrutide works

Retatrutide keeps both of tirzepatide’s receptors and adds glucagon’s. That receptor tells the liver to burn stored fat and raises how much energy the body spends, so calories burned join the calories GLP-1 and GIP cut.

It leans even further toward GIP, at 8.9 times the natural hormone, with 0.4 times natural GLP-1 and 0.3 times natural glucagon (Coskun, Cell Metabolism, 2022). Glucagon alone raises blood sugar, and the GLP-1 and GIP arms hold it down.

Its evidence is newer but broad: six positive Phase 3 trials between December 2025 and October 2026, in obesity, type 2 diabetes, heart disease and knee osteoarthritis.

Retatrutide vs tirzepatide weight loss comparison

Retatrutide comes out ahead at every comparable dose. In TRIUMPH-1, 2,339 adults with obesity and no diabetes lost an average of 19.0% on 4mg, 25.9% on 9mg and 28.3% on 12mg over 80 weeks, against 2.2% on placebo (Jastreboff, New England Journal of Medicine, 2026). In SURMOUNT-1, tirzepatide’s matching trial of 2,539 adults, 5mg took off 16.0%, 10mg 21.4% and 15mg 22.5% over 72 weeks, against 2.4% on placebo (Jastreboff, New England Journal of Medicine, 2022). Both sets count people who stayed on treatment, the figure each program leads with.

At the top doses, retatrutide averaged 5.8 points more weight loss. Its trial ran eight weeks longer, but the gap doesn’t depend on that: retatrutide 12mg had already reached 24.2% by week 48 in its Phase 2 trial, more than tirzepatide 15mg reached in 72. On 12mg retatrutide, 45.3% of people lost 30% or more of their body weight. On 15mg tirzepatide, 57% lost 20% or more.

Retatrutide also kept going. People who started with a BMI of 35 or more and stayed on 12mg reached 30.3% at 104 weeks, about 85 lb. How Long Does Retatrutide Take to Work? follows that curve from the first month.

Counted the stricter way, with everyone randomized included whether they stayed on or not, the gap holds: 25.0% on retatrutide 12mg against 3.9% on placebo, and 20.9% on tirzepatide 15mg against 3.1%.

Retatrutide vs tirzepatide with type 2 diabetes

Diabetes trims the result on every drug in this class, and retatrutide keeps its lead: 20.8% on 12mg in TRIUMPH-2 (Bellido, The Lancet, 2026), against 15.7% on tirzepatide 15mg in SURMOUNT-2 (Garvey, The Lancet, 2023). Tirzepatide posted the bigger A1C drop in that pairing, about 2.1 points from a starting 8.0%, against up to 1.6 points for retatrutide from 7.7%.

Retatrutide vs tirzepatide vs semaglutide

Semaglutide is the nearest thing to a shared yardstick, because both have now beaten it head to head. Tirzepatide took off 20.2% against 13.7% for semaglutide over 72 weeks in SURMOUNT-5, in adults with obesity (Aronne, New England Journal of Medicine, 2025). Retatrutide’s turn came on October 28, 2026: in TRANSCEND-T2D-2, 1,298 adults with type 2 diabetes lost 20.9% on retatrutide 12mg against 9.4% on Ozempic 2mg over 80 weeks, more than double, with a larger A1C drop as well (2.2 points against 1.8).

Retatrutide vs tirzepatide muscle loss

Both take off mostly fat. In a SURMOUNT-1 body-scan group of 160 people, about 75% of the weight tirzepatide removed was fat and 25% lean mass, the same split as on placebo. In a 36-week Phase 2 study in type 2 diabetes, retatrutide cut fat mass by 26.1% on 8mg and 23.2% on 12mg, with a lean share in line with other obesity drugs (Coskun, The Lancet Diabetes and Endocrinology, 2025). Because retatrutide removes more weight overall, the lean mass it takes adds up to more pounds.

Two racks of unlabeled analytical sample vials beside laboratory equipment

Is retatrutide stronger than tirzepatide?

Yes, measured by what each dose produced. The milligrams can’t be compared directly, because each molecule pulls at each receptor with a different strength, so the fair yardstick is the result in each compound’s obesity trial. Ranked from least to most weight lost, with the nausea rate and the share who stopped over side effects on each dose (placebo ran 14.8% and 4.9% in TRIUMPH-1, 9.5% and 2.6% in SURMOUNT-1):

Weekly doseAverage weight lossNauseaStopped for side effects
Tirzepatide 5mg16.0%24.6%4.3%
Retatrutide 4mg19.0%28.6%4.1%
Tirzepatide 10mg21.4%33.3%7.1%
Tirzepatide 15mg22.5%31.0%6.2%
Retatrutide 9mg25.9%38.4%6.9%
Retatrutide 12mg28.3%42.4%11.3%

What dose of retatrutide equals tirzepatide 15mg?

There is no exact conversion, but by result tirzepatide 15mg (22.5%) lands almost exactly halfway between retatrutide 4mg (19.0%) and 9mg (25.9%). On the trial ladder that midpoint is the 6mg step, a dose no Phase 3 group stayed on. Tirzepatide 10mg sits closest to retatrutide 4mg, and tirzepatide 5mg falls below every dose retatrutide’s trials kept people on.

TRIUMPH-5 will replace this with a direct answer. About 800 adults with obesity were randomized to one compound or the other for 80 weeks, with percent weight loss as the main result, and the trial is scheduled to reach that result in November 2026.

Retatrutide vs tirzepatide for fatty liver (MASH and NASH)

Retatrutide clears more liver fat on scans, and tirzepatide is the one with biopsy results. The glucagon arm acts on the liver directly, while tirzepatide reaches it mostly through the weight it takes off.

In 98 people with fatty liver from retatrutide’s Phase 2 trial, 12mg cut liver fat by 82.4% in 24 weeks, and 86% of them reached the normal range, against none on placebo (Sanyal, Nature Medicine, 2024). Tirzepatide 10mg and 15mg took liver fat down by about half over 52 weeks in type 2 diabetes, 8.1 points from a 15.7% start (Gastaldelli, The Lancet Diabetes and Endocrinology, 2022).

MASH, the inflamed form once called NASH, is judged by biopsy, and only tirzepatide has reported one. In SYNERGY-NASH, 190 adults with MASH and moderate or severe scarring took it for 52 weeks: MASH cleared without worse scarring in 62% on 15mg against 10% on placebo, and scarring improved a stage in 51% against 30% (Loomba, New England Journal of Medicine, 2024).

SYNERGY-OUTCOMES now tests both, each against its own placebo, in about 4,500 adults with high-risk fatty liver over about 224 weeks, with cirrhosis and death among the measures. Its main result is due in 2030.

Which is better: retatrutide or tirzepatide?

For the most weight loss, retatrutide. For the longer record and the gentler top dose, tirzepatide.

When to choose retatrutide

When the goal is the most weight lost. Retatrutide’s 9mg and 12mg doses beat tirzepatide’s top dose in every comparable trial, its 4mg dose came within 2.4 points of tirzepatide 10mg with fewer people stopping, and it more than doubled Ozempic’s result. In TRIUMPH-3 it also lowered hsCRP, an inflammation marker, by 51.2%. For someone stalled at tirzepatide 15mg, retatrutide 9mg and 12mg are the only doses in either program that went further.

When to choose tirzepatide

When the record matters more than the last few points. Tirzepatide has been approved since 2022, has finished outcome trials retatrutide hasn’t reached yet, and is the one with biopsy-proven MASH results. Its 15mg dose brought less nausea and vomiting than retatrutide 12mg, fewer people stopping and almost none of retatrutide’s skin sensitivity. For someone doing well on tirzepatide, that is a reason to stay.

Retatrutide vs tirzepatide dosage and reconstitution

Both trial programs start low and step up every four weeks. Retatrutide starts at 2mg and climbs through 4mg, 6mg and 9mg to 12mg from week 17. Tirzepatide starts at 2.5mg and adds 2.5mg every four weeks to 15mg from week 21, so retatrutide reaches its top dose four weeks sooner.

The trials held retatrutide at 4mg, 9mg or 12mg and tirzepatide at 5mg, 10mg or 15mg. Units follow the water, not the compound: with 1mL of water for every 10mg in the vial, each 1mg is 10 units on a U-100 syringe, so retatrutide’s 2mg start is 20 units and tirzepatide’s 2.5mg start is 25. The Retatrutide Dosage Chart and Tirzepatide Dosage Chart cover every vial size, and the Peptide Calculator works out any other mix.

Both arrive as a freeze-dried powder. Bacteriostatic water goes in slowly down the glass, and the vial is swirled, not shaken, until clear. A mixed vial keeps 28 days in the fridge at 2–8°C (36–46°F), enough for five weekly doses. How to Reconstitute Retatrutide and How to Reconstitute Tirzepatide go step by step, and Simms Research’s Research Water is $20 for 10mL.

Retatrutide vs tirzepatide cost

Per vial, retatrutide costs more. At Simms Research, Retatrutide (GLP-3) runs $84 for 10mg and $259 for 60mg, and Tirzepatide (GLP-2) $65 and $186. Per week the gap nearly closes, because retatrutide’s doses are smaller. A mixed vial keeps 28 days in the fridge, so each weekly figure here uses the vial with the lowest cost per dose inside that window.

Step for step, retatrutide costs within a few dollars a week of tirzepatide and delivered more weight loss. Retatrutide 4mg (19.0% average weight loss) comes to $26 a week, against $24 for tirzepatide 5mg (16.0%). At the top, retatrutide 12mg (28.3%) comes to $52 a week against $47 for tirzepatide 15mg (22.5%).

The middle of the range is where tirzepatide is cheapest. Tirzepatide 10mg comes to about $37 a week from a 60mg vial, five doses with 10mg left over, while retatrutide 9mg comes to $52 from the same size. Matched by result instead, retatrutide 4mg at $26 a week lands within 2.4 points of tirzepatide 10mg for $11 a week less.

Larger orders bring every weekly figure down further: three or more vials take 5% off, and six or more take 10%.

Two plain analytical sample vials beside laboratory testing equipment

Retatrutide vs tirzepatide side effects

The two share one family of side effects: nausea, diarrhea, constipation and vomiting, mostly mild to moderate and mostly during the months of dose increases. Most people on either compound never stopped over them: even on retatrutide 12mg, the dose with the highest rates in the table above, about 89% did not.

Matched by result instead of by rank, the two look alike. Retatrutide 4mg and tirzepatide 10mg produced similar weight loss, and retatrutide 4mg added 13.8 points of nausea over its placebo against 23.8 for tirzepatide 10mg. Fewer people stopped retatrutide 4mg (4.1%) than stopped its placebo (4.9%). At the top, retatrutide 12mg brings more stomach trouble than tirzepatide 15mg, with vomiting at 25.3% against 12.2% and constipation at 26.1% against 11.7%, and a result tirzepatide never reached.

Dysesthesia: the side effect that sets retatrutide apart

Dysesthesia is an altered sense of touch: skin that tingles, burns or reacts oddly to clothing. It showed up in every retatrutide Phase 3 trial and rose with dose, from 5.1% on 4mg to 12.5% on 12mg in TRIUMPH-1, against 0.9% on placebo. In TRANSCEND-T2D-2 it ran 4.8% to 6.5%, against 2.7% on Ozempic. Tirzepatide’s obesity trials put it at 0.4% or less. Most cases were mild to moderate, and most cleared while people kept taking retatrutide. Tirzepatide’s full list is in What Are the Side Effects of Tirzepatide?

Can retatrutide and tirzepatide be combined?

No trial has combined them. Both act on the GIP and GLP-1 receptors, so the pair doubles up on the same targets, and stomach side effects already rise with dose on each. Retatrutide alone covers both of tirzepatide’s receptors, with glucagon on top. The usual path is one after the other: tirzepatide first, retatrutide when the weight loss stalls.

Switching from tirzepatide to retatrutide

Take the first retatrutide dose on the day the next tirzepatide dose would have been due. Tirzepatide fades slowly, with about 38% of the last dose still working a week later and 14% after two weeks, so the old compound tapers off while the new one builds. No trial has tested the switch itself: retatrutide’s Phase 3 trials started everyone at 2mg and excluded anyone who had used a weight-loss drug in the previous 90 days.

Retatrutide starting dose after tirzepatide

The trials’ answer is 2mg, and the ranking above shows what that means for someone coming off a high tirzepatide dose. Retatrutide 2mg sits below its own 4mg step, which already trails tirzepatide 10mg and 15mg, so appetite often comes back for a few weeks while the dose climbs. By 9mg it has passed tirzepatide 15mg’s result. In Phase 2, starting at 2mg instead of 4mg cut the stomach side effects, and the glucagon receptor is new to anyone arriving from tirzepatide, which is the case for climbing through each step rather than jumping straight to 9mg.

Retatrutide vs tirzepatide FDA status in 2026

Tirzepatide is approved and retatrutide is not yet. Tirzepatide became Mounjaro for type 2 diabetes in May 2022 and Zepbound for weight loss in November 2023, and Zepbound added obstructive sleep apnea in December 2024.

Lilly plans to submit retatrutide to the FDA in the first quarter of 2027, for obesity, sleep apnea and knee osteoarthritis pain, which puts a decision between September 2027 and March 2028. When Will Retatrutide Be FDA Approved? lays out the timeline.

Frequently asked questions

Why is tirzepatide called GLP-2 and retatrutide GLP-3?

Research stores number them by the receptors they switch on: two for tirzepatide, three for retatrutide. What Is GLP-3 explains where the labels come from and why the middle one is misleading.

Does Eli Lilly make both retatrutide and tirzepatide?

Yes. Lilly developed both: tirzepatide as LY3298176, now Mounjaro and Zepbound, and retatrutide as LY3437943, its successor with the glucagon arm added. Retatrutide Code Names covers the labels it has gone by.

How does retatrutide compare with mazdutide?

Mazdutide is a dual agonist of GLP-1 and glucagon, so it shares retatrutide’s glucagon arm but lacks the GIP arm that retatrutide and tirzepatide have in common.Mazdutide vs Retatrutide puts their trial results side by side.

How do you know which one is in the vial?

By mass. Retatrutide weighs 4,731.3 g/mol and tirzepatide 4,813.5, a gap LC-MS testing separates easily. Simms Research’s current batches of both were tested by an independent lab on July 16, 2026, three vials each: retatrutide at 99.61% purity with 10.68mg in a 10mg vial, tirzepatide at 99.78% with 10.57mg, each with identity confirmed by LC-MS and passing endotoxin, heavy metal and microbial screens. The certificates are in the retatrutide and tirzepatide lab results.

Are retatrutide and tirzepatide for human use?

No. Simms Research sells both for laboratory research use only.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results